- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05715073
Improving Cognition With Neurodegradation Countermeasure
Improving Neuroprotection, Cognitive Function, and Mental Focus With Neurodegradation Countermeasure
The goal of this randomized, placebo-controlled, three-condition, double-blind, within-participants crossover clinical trial is to compare caffeine, TeaCrine plus caffeine, and a placebo condition in ROTC or tactical personnel.
The main question it aims to answer is the effect of the condition on measures of cognitive performance, cardio-autonomic, and hemodynamic responses after a physically demanding protocol.
The physiological function will be derived from metrics of heart rate variability, whilst cogntive performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.
Participants will report to the lab 4 times, once for familiarization of cognitive measures and then 3 times for their experimental visits. Participants will consume their randomized condition an hour prior to the fatiguing interval exercise protocol. Following they will complete a series of cognitive tasks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Columbia, South Carolina, United States, 29208
- University of South Carolina Sport Science Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is in good health and able to participate in high-intensity exercise.
- Participant is physically active: participating in resistance and/or endurance exercise ≥4 d/wk and ≥150 min/wk for ≥6 mo.
- Participant habitually consumes ≤240 mg caffeine/d (the equivalent of 3 cups of coffee).
- Participants will be asked about dietary supplementation use within the past 6 months.
(If Participant began taking a supplement within the past month, the Participant will be asked to discontinue supplement use followed by a 2-week washout prior to participation. In all other cases, supplement use will be asked to be maintained throughout the study).
Exclusion Criteria:
- Participant currently taking any prescription stimulants (i.e., Adderall, Ritalin, Vyvanse, etc.)
- Participant with any metabolic disorder including known electrolyte abnormalities, diabetes, thyroid disease, adrenal disease or hypogonadism.
- Participant with any inborn error of metabolism.
- Participant with a history of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
- Participant with sickle cell trait.
- Participant with a personal history of heart disease, high blood pressure (systolic >140 mm Hg & diastolic >90 mm Hg), psychiatric disorders, cancer, benign prostate hypertrophy, gastric ulcer, reflux disease, or any other medical condition deemed exclusionary by the medical staff.
- Participant currently taking thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, or anti-coagulant medications.
- Participant who has a known allergy to any of the ingredients in the supplement or the placebo.
- Participant who has migraines.
- Participant with a history of caffeine sensitivity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TeaCrine and caffeine
150mg of Teacrine and 150mg of caffeine
|
Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
|
|
Active Comparator: Caffeine
300mg of caffeine
|
Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
|
|
Placebo Comparator: Placebo
300mg of cellulose
|
Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in blood lactate
Time Frame: On the experimental visit days: Min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40)
|
Changes in blood lactate across the experimental visit
|
On the experimental visit days: Min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40)
|
|
Changes in Autonomic Nervous System Function (ANS) by linear metrics
Time Frame: On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
To determine if the intervention impacts ANS function by measuring heart rate variability represented by linear time domain metrics.
|
On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
|
Changes in Autonomic Nervous System Function (ANS) by nonlinear metrics
Time Frame: On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
To determine if the intervention has an impact on ANS function by measuring heart rate variability represented by nonlinear (ApSaEn) time domain metric.
|
On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
|
Changes in Autonomic Nervous System Function (ANS) by frequency domain metrics
Time Frame: On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
To determine if the intervention has an impact on ANS function by measuring heart rate variability represented by frequency domain metrics.
|
On the experimental visit days, this will be measured on a second by second basis from the beginning to the end of the visit (approximately 2 hours)
|
|
Changes in Inhibitory Control by reaction time (Go/No go)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on inhibitory control by measuring reaction time to Go targets (hits).
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Inhibitory Control by reaction time by errors(Go/No go)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on inhibitory control by measuring errors of commission representing incorrect responses to the target NoGo (false alarm).
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Attention (Go/No go)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the device has an impact on attention by measuring errors of omission to the target Go (misses).
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Inhibitory Control by accuracy scores (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on inhibitory control measured by the accuracy scores (% of correct answers) for compatible-congruent, incompatible-congruent, compatible-incongruent, and incompatible-incongruent Flanker Task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Inhibitory Control by average response time (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on inhibitory control measured by the average response time to incongruent flanker task trials irrespective of compatible or incompatible rule sets.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Inhibitory Control by commission errors (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
o determine if the intervention has an impact on inhibitory control measured by the commission errors when an individual fails to respond correctly to a flanker task trial, and commission error runs when an individual fails to respond correctly to multiple successive trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Attention by accuracy (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on attention measured by the accuracy scores for congruent-compatible Flanker task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Attention by average response time (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on attention measured by the overall average response time (milliseconds) to compatible and incompatible Flanker task trails irrespective of trial congruency.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Attention by omission errors (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on attention measured by the omission errors when an individual fails to respond to a flanker task trial, and omission error runs when an individual fails to respond to multiple successive trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Cognitive flexibility by accuracy (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on cognitive flexibility by the accuracy scores for incongruent-incompatible Flanker task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Cognitive flexibility by average response time (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on cognitive flexibility measured by the average response time to incongruent-incompatible flanker task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Cognitive control by post-error accuracy (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on cognitive control measured by post-error accuracy on Flanker task trials following an error.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Cognitive control by sequential congruency effect (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine changes in cognitive control measured by sequential congruency effect when lower interference occurs following an incongruent relative to a congruent flanker task trial reflecting a consciously controlled narrowing of attention to the central target.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Cognitive control by inverse efficiency (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on cognitive control measured by inverse efficiency a metric of a speed-accuracy trade-off for Flanker task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Attentional Inhibition (Flanker Task)
Time Frame: On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an impact on attentional inhibition measured by congruency interference representing the costs associated with the interference demands associated with incongruent vs congruent flanker task trials.
|
On the experimental visit days: minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in Rating of Perceived Exertion
Time Frame: On the experimental visit days: baseline at minute 0, minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
To determine if the intervention has an effect on perceived exertion, measured by Borg's Rating of Perceived Exertion scale from 6 to 20.
Higher measures indicate more exertion.
|
On the experimental visit days: baseline at minute 0, minutes 10, 22, and 30 during the exercise protocol, and 30 minutes after the exercise protocol
|
|
Changes in mood Brunel University Mood Scale (BRUMS).
Time Frame: On the experimental visit days: baseline at minute 0, immediately after completion of the exercise protocol at approximately 90 minutes into the visit, and 30 minutes after the exercise protocol approximately 120 minutes into the visit
|
To determine if the intervention has an effect on mental fatigue and mood.
|
On the experimental visit days: baseline at minute 0, immediately after completion of the exercise protocol at approximately 90 minutes into the visit, and 30 minutes after the exercise protocol approximately 120 minutes into the visit
|
|
Changes in Object Hit and Avoid
Time Frame: On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
To determine the effects of the intervention on rapid response execution and inhibition during complex continuous task performance.
|
On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
|
Changes in Anti-Saccade Task
Time Frame: On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
To determine the effects of the intervention on higher level processes, assessing response inhibition, working memory, and visuospatial attention.
|
On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
|
Changes in Modified Trail Making Task
Time Frame: On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
To determine the effects of the intervention on visuomotor processing and executive function.
|
On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
|
Changes in 2-Back Task
Time Frame: On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
The determine the effects of the intervention on working memory capacity.
|
On the experimental visit days: Immediately after and 30 minutes after the completion of the exercise protocol.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00123869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Change
-
University Ramon LlullAinhoa Nieto Guisado; Mònica Solana-TramuntUnknownCognitive Change | Proprioception Change | Balance ChangeSpain
-
Applied Science & Performance InstituteCompletedCognitive Change | Mood Change | Mental ProcessesUnited States
-
National Council of Scientific and Technical Research...CompletedSleep | Cognitive Change | Mood Change | CreativityArgentina
-
Mentage LLCNot yet recruitingCognitive Change | Aging | Healthy Aging | Health Behavior | Primary Care | Cognitive Wellness | Age-Related Cognitive Change
-
Heilongjiang Feihe Dairy Co. Ltd.CompletedCognitive ChangeChina
-
University of MiamiMcKnight Brain Research FoundationCompleted
-
University of Wisconsin, MadisonNational Institute on Aging (NIA); University of California, Irvine; University...Completed
-
Tufts UniversityCompleted
-
Northeastern UniversityNational Institute on Aging (NIA); University of California, RiversideCompletedCognitive ChangeUnited States
-
Western University, CanadaInteraXon, Inc.; Cambridge Brain SciencesCompletedCognitive ChangeCanada
Clinical Trials on TeaCrine and Caffeine
-
University of Mary Hardin-BaylorDymatize Inc.CompletedBlood Pressure | Mood | Heart Rate | Energy MetabolismUnited States
-
University of South CarolinaRutgers, The State University of New Jersey; Compound Solutions Inc.CompletedCaffeine, Teacrine, and Dynamine: Effects on PerformanceUnited States
-
University of RochesterNot yet recruitingInfants | Neonatal Apnea
-
Indiana UniversityIndiana Clinical and Translational Sciences InstituteRecruitingPremature Birth | Respiratory Distress Syndrome | Bronchopulmonary Dysplasia | Apnea of Prematurity | Preterm Labor With Preterm DeliveryUnited States
-
Universidad Rey Juan CarlosEnrolling by invitationExercise | Caffeine | Ergogenics | Cycling | Fat MetabolismSpain
-
Northumbria UniversityCompletedExercise | Dietary SupplementTurkey (Türkiye)
-
Southern Illinois University CarbondaleCompleted
-
Istanbul University - Cerrahpasaİstanbul Yeni Yüzyıl ÜniversitesiNot yet recruitingMuscle Strength | Exercise Performance | Adaptation | Muscle HypotrophyTurkey (Türkiye)
-
Sinop UniversityCompletedAthletic Performance | Cognitive Performance | Healthy Adult FemalesTurkey (Türkiye)
-
Universidad Pontificia ComillasEastern Mediterranean University; Northumbria University; Universidad Francisco... and other collaboratorsCompletedDietary Supplement | Sports PerformanceTurkey